Gujarat Themis Biosyn has completed the expansion of its Fermentation Block at its manufacturing facilities at Vapi, Gujarat. The first batch of commercial production of Rifamycin-S and Rifamycin-O has commenced on October 18, 2025.
With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL. This will further strengthen the company’s manufacturing capabilities to produce multiple fermentation products. With this capacity expansion, the company is in a strong position to capitalise on the significant growth opportunities in the fermentation segment.
Gujarat Themis Biosyn is a biotech and synthetic product manufacturing company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: